ReviewCureus2026
Levothyroxine Intake Timing During Ramadan in Patients With Hypothyroidism: A Systematic Review and Meta-Analysis of Research Findings.
Review in Cureus, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
0 citing papers in PubMed.
No citing paper in PubMed yet.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
8 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Daily medication is challenging in the Islamic holy month of Ramadan, particularly for patients on levothyroxine replacement therapy for hypothyroidism. Ramadan necessitates significant alterations to daily dietary habits and medication schedules, which may impact drug absorption and efficacy. This study aims to synthesize findings from existing research on the optimal timing of levothyroxine intake during Ramadan and to compare these results with established recommendations for nonfasting periods. By searching MEDLINE, PubMed, Google Scholar, Web of Science, and CENTRAL Cochrane Library databases from inception to May 2025, a systematic review and meta-analysis of randomized controlled trials (RCTs) and observational studies were conducted to evaluate the optimal timing of levothyroxine intake during Ramadan in patients with hypothyroidism. The study protocol was registered on PROSPERO (CRD420261284016). The primary outcome was thyroid-stimulating hormone (TSH) levels after Ramadan fasting. We used the standardized mean difference (SMD) with corresponding 95% confidence intervals (CIs) to synthesize results in the absence of heterogeneity. The risk of bias was assessed using Cochrane Risk of Bias 2 and Quality Assessment of Diagnostic Accuracy Studies 2 tools for RCTs and observational studies, respectively. We screened 214 records and included nine studies. A small but statistically significant increase was noted in post-Ramadan TSH levels compared with the prefasting levels (SMD = 0.29; 95% CI = 0.15-0.42; Z = 4.17; p < 0.001). However, most patients (79.8%) can maintain euthyroidism with different intake times (85.3%) if adherence is optimal. The results highlight various outcomes across different timings and the importance of patient adherence. Ultimately, rather than the timing of levothyroxine intake, adherence is the most likely factor determining the adequacy of thyroid function during and after Ramadan fasting.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.